M. E. Harper

Monash Health — Australia

Medicine · Health Sciences

29h-index5.2kcitations85works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(32), Hormonal and reproductive studies(25), Estrogen and related hormone effects(16), Prostate Cancer Diagnosis and Treatment(15), HER2/EGFR in Cancer Research(13)

Publications85 total

Optimising prostate cancer pathways: Improving post‐biopsy waiting times in a tertiary centre
BJUI Compass·2025Open Access
Prolactin Receptor — Clinical Problems
2020
Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour–stroma interactions
Endocrine Related Cancer·2006· 58 citedOpen Access
Role of PII Protein as a Signal Nitrogen Level in Herbaspirillum Seropedicae
Kluwer Academic Publishers eBooks·2005· 1 cited
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies
The Journal of Steroid Biochemistry and Molecular Biology·2005· 52 cited
Elevated c-met expression accompanies endocrine resistance in MCF7 breast cancer cells and promotes in vitro cell migration and invasion
ORCA Online Research @Cardiff (Cardiff University)·2005Open Access
Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer
International Journal of Cancer·2004· 44 cited
Chapter 16: beyond antihormones in the targeted therapy of breast cancer
ORCA Online Research @Cardiff (Cardiff University)·2004
Nonendocrine Pathways and Endocrine Resistance
Clinical Cancer Research·2004· 118 cited
Characterization of a transplantable hormone‐responsive human prostatic cancer xenograft TEN12 and its androgen‐resistant sublines
The Prostate·2003· 10 cited
Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; IRESSA™) in DU 145 human prostate cancer cells
European Urology Supplements·2003· 1 cited
Comparison of the androgen dependent prostatic cancer the TEN12 with its androgen independent sublines TEN12F and TEN12C using DNA arrays
European Urology Supplements·2003
The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
Endocrinology·2003· 170 citedOpen Access
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
Endocrinology·2003· 525 citedOpen Access
ZD1839 (‘Iressa’) improves the antitumour activity of tamoxifen (‘Nolvadex’) and ICI 182, 780 (‘Faslodex’) in antihormone responsive breast cancer
European Journal of Cancer·2002· 2 cited
Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer
Annals of the New York Academy of Sciences·2002· 65 cited
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor
The Prostate·2002· 20 cited
ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]
ORCA Online Research @Cardiff (Cardiff University)·2001· 3 cited
EGFR and cancer prognosis
European Journal of Cancer·2001· 2.1k cited
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
Endocrine Related Cancer·2001· 160 cited
page 1 of 5Next →

Frequent Co-authors

K. Griffiths(30), W.B. Peeling(12), Julia M.W. Gee(11), Lindy Goddard(11), Robert I. Nicholson(10), Denise Barrow(9), C. G. PIERREPOINT(8), Janice M. Knowlden(6), Iain R. Hutcheson(6), E Glynne-Jones(6), Douglas W. Wilson(5), Helen Jones(4), Eve Glynne‐Jones(4), A. R. Fahmy(4), Helen E. Jones(3), Alan E. Wakeling(3), Adrian W. Pike(3), R A McClelland(3), Nicola Jordan(3), A. E. Wakeling(3)